Takeda Pharmaceutical Co Ltd logo

Takeda Pharmaceutical Co Ltd

€ 27.23 (+4.05%) Oct 4
On watch
P/E:
30.67
P/B:
0.94
Market Cap:
€ 42.15B ($ 41.99B)
Enterprise V:
€ 69.86B ($ 69.60B)
Volume:
-
Avg Vol (2M):
115.00
Also Trade In:
Volume:
-
Market Cap €:
42.15B
Market Cap $:
41.99B
PE Ratio:
30.67
Avg Vol (2-Month):
115.00
Enterprise Value €:
69.86B
Enterprise Value $:
69.60B
PB Ratio:
0.94
GF Score:
Year:
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website Sources Stock Report
Dataset
Financial Download

Business Description

Description
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 3.6 trillion in fiscal 2021. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the U.S., 20% from Japan, 20% from Europe and Canada.

Financials (Next Earnings Date:2022-10-28 Est.)

WBO:TKD's 30-Y Financials

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
To

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

Valuation Box

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil €) 27,080.193
EPS (TTM) (€) 0.931
Beta 0
Volatility % 19.35
14-Day RSI 54.62
14-Day ATR (€) 0.311023
20-Day SMA (€) 26.815
12-1 Month Momentum % -2.72
52-Week Range (€) 23.75 - 28.34
Shares Outstanding (Mil) 1,546.1

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 5
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Takeda Pharmaceutical Co Ltd Filings

Document Form Filing Date
No Filing Data

Takeda Pharmaceutical Co Ltd Analysis

Share your research